Navigation Links
Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team
Date:9/22/2008

MONTREAL, Sept. 22 /PRNewswire/ -- Enobia Pharma, a biotech company focused on developing novel therapeutics for serious bone disorders, today announced key appointments to add commercial and manufacturing expertise to the Company's senior management team in conjunction with the recent initiation of two clinical trials of ENB-0040 for the treatment of hypophosphatasia.

Julie Anne Smith has been appointed as Enobia's Vice President, Chief Commercial Officer, and Jayant Aphale, PhD., MBA has been appointed as Vice President, Manufacturing and Process Sciences. Prior to joining Enobia, Ms. Smith was Vice President, Commercial at Jazz Pharmaceuticals Inc. where she led commercial strategy and operations. Previously, Ms. Smith was Vice President, Global Marketing for Genzyme and led the Global Marketing department for Genzyme's rare disease therapeutics business division. Her responsibilities included leading the worldwide commercialization and planning for Myozyme(R), an enzyme replacement therapy for ultra-orphan Pompe disease.

Dr. Aphale was the former Vice President Operations and Project/Portfolio Management at Acambis plc. At Acambis, Dr. Aphale was responsible for R&D project management as well overseeing multiple vaccine manufacturing plants, which included cGMP upstream and downstream manufacturing, and a lyophilization facility. Dr. Aphale previously held Director level positions at Wyeth Vaccines and Diosynth Biotechnology, a biologics contract manufacturing organization. Prior to that, Dr. Aphale was a senior scientist, cGMP manufacturing at Roche Molecular Systems where he was responsible for technology transfer and manufacturing and release of heat stable enzymes.

"Julie and Jayant are seasoned executives who bring to Enobia extensive industry experience that will be extremely valuable as we continue to progress our clinical program for hypophosphatasia and to prepare our commercial efforts," stated Robert Heft, PhD., Chief Execu
'/>"/>

SOURCE Enobia Pharma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Enobia Pharma Receives FDA Orphan Drug Designation for Hypophosphatasia Product Candidate ENB-0040
2. Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia
3. Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients
4. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
5. Memory Pharmaceuticals and Roche Expand R3487/MEM 3454 Development Program
6. Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform
7. Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline
8. VIA Pharmaceuticals to Present at American Heart Association Scientific Sessions 2008
9. Unibioscreen and Drais Pharmaceuticals Partner to Develop and Commercialize UNBS 5162 for Treatment of Cancer
10. Vanda Pharmaceuticals Provides Update on Iloperidone
11. Cerimon Pharmaceuticals Announces Positive Results from a Phase II Clinical Study of Its Diclofenac Sodium Patch for Acute Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... of the "Electrocardiogram (ECG) Devices - Global Trends, ... http://photos.prnewswire.com/prnh/20130307/600769 ... US$330 million by 2016. The North America ... global market share while Europe ...
(Date:12/15/2014)... Dec. 12, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/ms3j8c/cardiac ) has announced the addition of the ... 2012-2018"  report to their offering. Global Guidewires sector ... North America accounts for nearly ... Europe claims approximately 25% (2018). ...
(Date:12/15/2014)... NEW YORK and HERZLIYA PITUACH, Israel ... the "Company") (NASDAQ: IMNP ) announced today that ... of the Board succeeding Dr. Daniel Teper who ... been a member of Immune,s Board of Directors since 2013. ... comments: "I am delighted to represent the interest of shareholders ...
Breaking Medicine Technology:Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 4Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 3Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 4Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 2Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 3Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 4
... - Phase II Data Indicate Overall and Disease-Free ... Results from an adjuvant trial in,high-risk melanoma patients ... (sargramostim) achieved disease-free and/or overall,survival. These findings, which ... at the 44th annual meeting of the American ...
... SUNNYVALE, Calif., June 5 Pharmacyclics, Inc.,(Nasdaq: ... from a Phase 1/2 study showing a,46 ... multiply recurrent,non-Hodgkin,s lymphoma (NHL) who were treated ... Yttrium-90 Ibritumomab Tiuxetan,(Zevalin(TM)), an approved antibody-targeted radiation ...
Cached Medicine Technology:Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients 2Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients 3Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients 4Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients 5Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkin's Lymphoma 2Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkin's Lymphoma 3Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkin's Lymphoma 4
(Date:12/17/2014)... Alan Mozes HealthDay Reporter ... holiday party season fast approaching, a new study reveals that ... arrests have fewer drunk drivers on their roads. The ... vigilantly are better able to deter inebriated revelers from getting ... new laws are being passed regarding drinking and driving," said ...
(Date:12/15/2014)... Cancer researchers have just published an important new ... malignant pleural mesothelioma. Surviving Mesothelioma has just posted an ... here to read it now. , Doctors at ... New York’s Langone Medical Center performed complete genetic analyses ... an effort to pinpoint the genes that are most ...
(Date:12/15/2014)... SIMpalm, a leading mobile app development ... for its client, which allows users to keep track ... in finding the right wine. At the center ... sensory, chemistry and wine information. All this information is ... Those wines that are close counterparts to one another ...
(Date:12/15/2014)... -- Expert pilots process visual information more efficiently than ... decisions during landings, a new study shows. Landing ... to master, and 36 percent of all airplane crashes ... approach and landing. Researchers monitored the brain activity ... while they were at the controls of a flight ...
(Date:12/15/2014)... OR (PRWEB) December 15, 2014 ... seeks to bring attention to restrictive state laws ... position paper on this important area of public ... Laws Can Compromise the Integrity of Independent Review, ... and access of independent peer review determinations can ...
Breaking Medicine News(10 mins):Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 3Health News:New Study Reveals Genetic Mutations That May Trigger Mesothelioma, According to Surviving Mesothelioma 2Health News:Use WinMatch Connect App to Keep Track of Wines You Like 2Health News:Study Shows Why Expert Pilots Are Experts 2Health News:NAIRO Calls for Higher Quality Independent Peer Review By Ending Restrictive State Laws 2
... economy, the Rs 3,200-crore Indian health insurance industry is poised ... a growth rate of over 44 per cent per annum, ... insurers and even life insurers are jumping in the fray. ... instance, is planning to launch a health insurance product ...
... reportedly annoyed, for her upcoming tour bosses have asked her to ... is over . ,According to a source, although the ... was bugged by the contract as no other band member was ... requirement really, Geri isnt planning to get pregnant but she was ...
... snide remarks about her, claiming that the actress is too old ... Kutcher tied the knot in September 2005, and the actress became ... Guynes, who is separated from Moores half-brother commented that the 44-year-old ... was old. ,I think Demi is getting too old ...
... nanny for not turning up on time and lying to her ... her about visiting her dad in Wales, while she was actually ... care of her son Harvey as the nanny did not turn ... was criticized by Chris Moyles. ,Jordan went straight to ...
... with two felony counts of possession of a controlled substance, ... prescription and possession of marijuana, and a speeding infraction ... July 4. ,A law enforcement source revealed ... prescription drugs had been recovered from Albert Gore Thirds car. ...
... men are not influenced by advertisements that show horrific ... them, says a report . ,The ... dreadful consequences of drink-driving can influence young men not ... such public announcements show that a minimum penalty of ...
Cached Medicine News:Health News:Life Insurers in India to Launch Health Insurance Policies 2Health News:Drink-drivers Not Influenced by Ads Unless It Affects Them Personally 2
Inquire...
Inquire...
Inquire...
... range of 18 Ophthalmic frames created ... producted to the very hightest quality. ... lightweight Titanium and Beta Titanium models, ... of beautifully formed and innovative designs ...
Medicine Products: